Canton Strategic Holdings Inc (CNTN) is a dual-strategy company that combines a pre-revenue clinical-stage pharmaceutical business with a Canton Network-focused digital asset treasury operation. The company generates no product revenue as of the fiscal year ended December 31, 2025, funding operations through capital raises rather than commercial sales. In November 2025, CNTN closed a private placement raising net proceeds of approximately $537 million, split between roughly $90.9 million in cash and $446.2 million in cryptocurrency. The pharmaceutical pipeline includes GV023, an oral infliximab candidate licensed from Intract Pharma Limited under an exclusive global agreement (outside South Korea) signed September 11, 2024. The digital asset strategy centers on acquiring Canton Coin (CC) and participating in the Canton Network as a Super Validator and Validator node. The company reported cash used in operating activities of $16.0 million and a net loss of $42.1 million for the year ended December 31, 2025. Going concern doubt, previously disclosed, was removed following the November 2025 capital raise.

Revenue model

No product or service revenue is disclosed for the fiscal year ended December 31, 2025. Operations are funded through equity and debt capital raises. The digital asset treasury strategy is designed to generate returns through CC appreciation, validator rewards, staking, and network participation activities. Pharmaceutical revenue depends on future regulatory approval of product candidates, none of which have reached commercialization.

Products and services

GV023 (formerly TH023): an oral anti-tumor necrosis factor-alpha monoclonal antibody using infliximab, licensed via the Intract Agreement (September 11, 2024) on Intract Pharma's Soteria and Phloral delivery platforms. Canton Coin (CC): the native digital asset of the Canton Network, held as an indefinite-lived intangible asset on the balance sheet. Canton Network validator and Super Validator participation: block validation and staking activities on a permissioned distributed ledger.

Customers and end markets

No commercial customers are disclosed as of the fiscal year ended December 31, 2025. The pharmaceutical pipeline targets inflammatory disease indications addressable by TNF-alpha inhibition. The digital asset strategy targets capital from institutional and individual investors interested in Canton Network-native assets.

Value-chain role

In pharmaceuticals, CNTN is a clinical-stage licensee dependent on third parties for manufacturing, clinical trials, and regulatory approval. It does not own or operate manufacturing facilities. In digital assets, CNTN operates as a network participant, Super Validator, and treasury accumulator on the Canton Network, a permissioned distributed ledger.

Geographic exposure

GV023 license rights cover global development and commercialization outside of South Korea. No other geographic revenue or operational breakdown is disclosed in the filing.

Competitors

digital asset treasury companies, tokenization and real-world asset platforms, digital asset investment vehicles and ETPs, private funds and venture-backed entities focused on blockchain infrastructure

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: Allarity Therapeutics Inc Windtree Therapeutics Inc BELLICUM PHARMACEUTICALS, INC Plus Therapeutics Inc CervoMed Inc Decoy Therapeutics Inc Lixte Biotechnology Holdings Inc LogicBio Therapeutics, Inc. ProtoKinetix Inc